Trials Near Add Your Location

Accepting patients

ELEMENT-MDS

Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
Learn more
  • Erythroid Maturation Agent (EMA)
  • Erythropoiesis-Stimulating Agent (ESA)
  • Red Blood Cell Stimulant
  • Phase 3

Accepting patients

Bone Marrow & Kidney Transplant

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders (BMT)
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Identifying Barriers to Allo Stem Cell Transplants

Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Learn more
  • Pre-Allogeneic Stem Cell Transplant
  • Observational Trial

Accepting patients

Smart Immune

Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT
Learn more
  • Phase 1/2

Accepting patients

Antibiotics During Stem Cell Transplant

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

PTSD Mobile App

PTSD Mobile App for Cancer Survivors
Learn more
  • Observational Trial

Accepting patients

SEA-CD70

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies
Learn more
  • Monoclonal Antibody
  • Phase 1

Not yet accepting

NEXI-001

Phase 1b Expansion Study of Multi-Antigen Specific CD8+ T Cells After Decitabine-enhanced Lymphodepletion: an Adoptive Cellular Therapy for Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from Matched HLA Donors
Learn more
  • Allogeneic Stem Cell Transplant
  • T Cell (Allogeneic)
  • Post-Allogeneic Stem Cell Transplant
  • Phase 1

Not yet accepting

Lisaftoclax

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
Learn more
  • BCL-2 Inhibitor
  • Placebo
  • Randomization
  • Phase 3

Accepting patients

PROMISE

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Learn more
  • High Risk
  • Observational
  • Observational Trial